Covidien revamps revenue reporting, warns foreign exchange rates will hurt; J&J/DePuy rolls out new elbow prosthesis system;

@FierceMedDev: Mindray climbs back from damage done on Twitter. Article | Follow @FierceMedDev

@MarkHFierce: Solta Medical, an aesthetic med device maker with sagging sales, will sell itself for $250M. Reorganization wasn't enough. Story | Follow @MarkHFierce

@MichaelGFierce: To deliver drugs, German engineers took a cue from some of the best swimmers in nature: sperm cells. More from FierceDrugDelivery | Follow @MichaelGFierce

@GalenMoore: Here's what 21 tweets can do to your reputation: Mindray climbs back from damage done on Twitter. More | Follow @GalenMoore

> Covidien ($COV) is revamping how it reports revenue from its various business segments, and the company also warns that foreign exchange rates could negatively affect its fiscal 2014 guidance. Item

> Johnson & Johnson's ($JNJ) DePuy Synthes division is launching a new prosthesis system in the U.S. for joint replacement in the elbow. Item

> A long-time executive credited with building Varian Medical Systems' ($VAR) X-Ray Products division is retiring this February. Item

> Corgenix said it has made its 510(k) submission with the FDA for its TxBCardio urine test. Item

> InVivo Therapeutics has brought in a veteran Biomet executive as its interim chief financial officer. Item

Biotech News

@FierceBiotech: Genzyme's Lemtrada has been approved in Canada for treatment of multiple sclerosis. Release | Follow @FierceBiotech

@JohnCFierce: Why is it a CEO can't be fired or quit? Amarin's Joe Z "retires." joins a long list of biotech retirees who either jumped or were pushed. More | Follow @JohnCFierce

@DamianFierce: Genentech wrote a solid guide to some of the methodology used in the much-discussed I-SPY 2 studies. More from Genetech | Follow @DamianFierce

@EmilyMFierce: Booster of red blood cells synthesized for first time. Story via SciAm | Follow @EmilyMFierce

> Cubist bounces along with more promising PhIII antibiotic results. News

> AcelRx spikes on $250M deal for late-stage pain drug/device Zalviso. More

> CEO of troubled Amarin heads for the exit as FDA readies Vascepa decision. Article

> Agenus mounts a comeback on positive results for its brain cancer vaccine. Story

Pharma News

@FiercePharma:  Endo to Acquire Specialty Pharmaceutical Company NuPathe. Release | Follow @FiercePharma

@EricPFierce: Bloomberg says drugmakers make catch a break on in Germany, price cuts and rebates may fall next year. More | Follow @EricPFierce

@CarlyHFierce: Sanofi signs on to sell Vivus ED drug in emerging markets. Friday's story | Follow @CarlyHFierce

> China rounds up counterfeiters as the FDA boosts its oversight there. More

> GlaxoSmithKline bets another $1B on India with stake-raising buyout offer. News

> More new drugs, yes. Lots more sales? Not always, thanks to skeptical payers. Story

CRO News

> Oxygen Bio taps Duke's in-house CRO to run Phase III for its cardio drug. Story

> Quotient Clinical is the latest CRO snapped up by private equity. Report

> Belgian CRO Genae reaches into Switzerland for medical device work. News

> Bayer teams up with Texas' MD Anderson for cancer clinical trials. More

> Charles River shakes up its leadership to cut costs and boost sales. Article

> CROS NT names a new CEO amid its global push. Item

Biotech IT News

> Twitter-driven stock furor prompts exchange to fine Medivir. More

> Court fines Boehringer $1M for 'gross inadequacy' of record keeping. News

> Merck turns to gamification to help Type 2 diabetics. Article

> Accelrys inks $50M Qumas takeover to continue deal-driven expansion. Report

> BGI is building a huge genome database to drive drug discovery. Story

> NIH names its first associate director of data science. Item

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.